Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 308Carcinoma, Non-Small-Cell Lung 241Prostatic Neoplasms 198Neoplasms 191Lung Neoplasms 149Multiple Myeloma 144Neoplasm Metastasis 110Colorectal Neoplasms 105Melanoma 97Ovarian Neoplasms 90Leukemia, Myeloid, Acute 81Pancreatic Neoplasms 77Lymphoma 76Leukemia, Lymphocytic, Chronic, B-Cell 71Brain Neoplasms 70Carcinoma, Renal Cell 68Lymphoma, Non-Hodgkin 64Squamous Cell Carcinoma of Head and Neck 62Carcinoma, Hepatocellular 61Hematologic Neoplasms 59Urinary Bladder Neoplasms 58Recurrence 56Head and Neck Neoplasms 56Triple Negative Breast Neoplasms 55Glioblastoma 53Endometrial Neoplasms 52Uterine Cervical Neoplasms 51Lymphoma, Follicular 51Sarcoma 46Precursor Cell Lymphoblastic Leukemia-Lymphoma 46

Interventions

durvalumab 1Gemcitabine 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Locally Advanced or Metastatic Solid Tumours × 90 days × Clear all
NCT04999969 2026-04-30

Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours

AstraZeneca

Phase 2 Active not recruiting
126 enrolled 30 charts
Other solid neoplasm

Locally Advanced or Metastatic Solid Tumours

Data powered by HemOnc (CC BY 4.0) Colophon âš¡